OM
AQST icon

Opaleye Management’s Aquestive Therapeutics AQST Stock Holding History

Opaleye Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-738,500
Closed -$4.3M – 45
2019
Q4 		$4.3M Buy
+738,500
New +$3.84M 0.84% 38
2019
Q3 		– Sell
-590,000
Closed -$2.48M – 50
2019
Q2 		$2.48M Buy
+590,000
New +$3.02M 0.76% 35

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management's AQST Position: Q1 2020 in Review

Opaleye Management sold out of Aquestive Therapeutics (AQST) in Q1 2020, closing a stake of 738,500 shares — an estimated $4.3M sold.

Opaleye Management first reported a position in AQST in Q2 2019 and held it in 2 quarters. The position peaked at $4.3M in Q4 2019. 42 funds tracked by Wall St. Rank hold AQST as of Q1 2020.

  • Opaleye Management reported no remaining Aquestive Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Opaleye Management sold 738,500 Aquestive Therapeutics shares in Q1 2020, an estimated $4.3M.
  • Opaleye Management first reported a position in Aquestive Therapeutics in Q2 2019 and held it in 2 quarters.
  • Opaleye Management's Aquestive Therapeutics position peaked at $4.3M in Q4 2019.
  • 42 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2020.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.